Navigation Links
New treatment approach promising for lymphoma patients in the developing world
Date:7/6/2008

Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.

At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, a group headed by Prof. Hamdy Azim from Cairo University reports that giving these patients chemotherapy every 2 weeks, rather than every 3 weeks as usual, improved treatment outcomes.

The standard regimen in this case is called CHOP (chemotherapy regime), which is given every 3 weeks. In the developed world, CHOP is administered in combination with an antibody therapy called rituximab.

But many patients in developing countries, including Egypt where this study was conducted, cannot afford this treatment, so they are offered CHOP alone.

"We hypothesized that if CHOP or a CHOP-like regimen was given every two weeks instead of three, a superior outcome could be achieved," says Dr. Hatem A. Azim Jr, who presented these results at ECLU.

To see if this was the case, they analyzed five trials that compared CHOP to regimens given every two weeks. Using two statistical analyses, they showed that regimens every two weeks had superior response rate, disease-free and overall survival; however in one method, the response rate analysis did not reach statistical significance.

"We believe that this work could provide good evidence to support the use of the 2-weekly regimen," Dr. Azim Jr said. One issue that remains to be assessed is how well patients tolerate the more intense treatment, he noted.

"Patients on the 2-weekly regimens have to receive injections with 'growth factors' to ensure that severe toxicities to the white blood cells do not occur," he said. "Even so, the cost of these injections per cycle is much lower than that of rituximab. The preliminary results are encouraging in providing patients who cannot afford the cost of rituximab, a bet
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

1

GOOD

Page: 1 2

Related biology news :

1. Treatment delays result in poor outcomes for men with breast cancer
2. Counting tumor cells in blood predicts treatment benefit in prostate cancer
3. Stroke study reveals key target for improving treatment and suggests that Gleevec may help
4. Hypertension treatment effective in reversing vascular damage
5. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
6. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
7. Novel therapeutic strategy for colon cancer treatment
8. New ballast treatment could protect Great Lakes fish
9. Quest for better treatment for effects of menopause
10. Sugar linkage could lead to better treatment for autoimmune diseases
11. Glypican-3 gene function in regulating body size helps inform novel cancer treatments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... December 2009 print issue of The FASEB Journal ...r their fertility that women have had since the 19...where androgenic hormones work in the testis to co...This opens a promising avenue for the development ...ope to those who cannot have children because of l...
(Date:11/30/2009)...dioactive gas that is produced by the radioactive ...cay and is found in trace amounts naturally in nea...uilding materials, plants, animals, and the human ... amount of radiation that would be emitted by rado...he units are picocuries per liter (pCi/L). The Ame...
(Date:11/26/2009)...ed deer have been caught in the hunters, sights fo...than decorative. They are lethal weapons that stag...The University of York, UK, has been intrigued by ...century and has become fascinated by the mechanica...laboration with Tomas Landete-Castillejos at the U...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Tough yet stiff deer antler is materials scientist's dream 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4
... written book describes hundreds of well-known and...rporate leaders, and literary greats who used or a...esidents, seven popes, Sir William Osler, J.D. Roc...re among those famous people who were known to hav...ngly is the evidence of Charles Darwins use of hom...
...o the way in which parasites interact with each ot...e likely to break out. , A group of scientists i...r of infectious parasites in rabbits. The findings...ssfully when infectious cyclical diseases in human...niversitys School of Biosciences, University of St...
...ses, such as when to multiply, are often regulated... of interactions between proteins. North Carolina ...y in which a specific protein-protein interaction ... off, leading to uncontrolled cell proliferation ...ished in the December 2007 edition of the Cell Pre...
Other Biology News:The surprising story of Charles Darwin and his homeopathic doctor 2The surprising story of Charles Darwin and his homeopathic doctor 3Can interacting pathogens explain disease patterns? 2Why the switch stays on 2Why the switch stays on 3
(Date:11/30/2009)... PDS, a leader in providi... community, announces Pajama Pathology®, evolu...ng the same ‘gold standard’ software u... the world, but on a ‘cost per slide’ ... NJ (PRWEB) November 30, 2009 -- PDS has announced...
(Date:11/30/2009)..., , AMSTERDAM...the world,s,leading publisher of scientific, medic...unced a major re-launch of Embase, its comprehensi... indexed records from more than 7,000,active, peer...yed a key role in the advancement of new biomedica...
(Date:11/27/2009)... A mechanised blue dye t...ion to packaging quality assurance one step closer...n-contact leak testing machine developed by Sep...been installed in several local and global pharma-...to address quality assurance and productivity impr...
(Date:11/25/2009)..., , ,, BOCA RATON, ... 2009 has been a painful year. Not so for BodyLogi...work of expert physicians specializing exclusively...as grown the number of physicians in its netwo...ns - and is in progress to add more physician-own...
Breaking Biology Technology:Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4
...rta and the National Research Council,s National I... an approach that is leading to improved performan...lls). The development of inexpensive, mass-produce...st for many of the world,s scientists and engineer...ra-high purity silicon and other materials normall...
...ates Anti-Tumor Activity Across Doses and Endpoint... Patients - , , - Data To Be Presented at ASCO,s ...vation to Host Conference Call and Webcast Present...tern Time - , , SAN FRANCISCO, Feb. 25 Medivati...sentation of new efficacy and safety data from an ...
...harmaceuticals Inc.,(Nasdaq: TRBN ) today announ...cent, or 25 employees, and a corporate restructuri...apital markets and the global economy, Trubion,is ...lign its current,resources with its strongest near...for long-term sustainability and success. , Fo...
Other Biology Technology:University of Alberta and NINT researchers make solar energy breakthrough 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 5Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 2Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 3Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring 4
X-gal from BioPioneer
Angiogenesis Tube formation Assay Kit from Upstate
Monkey IL-6 ELISPOT Kit, With white/opague microtiter plates from Cell Sciences
Histone Deacetylase Radiometric (3H) Assay Kit from Upstate
Biology Products: